Search results
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF...
WKRN Nashville· 6 days agoFood and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a ...
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Clinical Trials Arena via Yahoo Finance· 2 days agoVerastem stated the dose cohort was cleared after additional patients were evaluated. Avutometinib...
FDA lifts hold on Larimar's Friedreich's Ataxia drug study By Investing.com
Investing.com· 6 days agoLarimar Therapeutics, Inc. (NASDAQ:LRMR), a biotechnology firm engaged in developing treatments for...
Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
Zacks via Yahoo Finance· 3 days agoThe RMAT designation is generally granted by the FDA to therapies that are intended to treat or cure...
FDA grants Cartesian Therapeutics RMAT status for MG therapy By Investing.com
Investing.com· 4 days agoCartesian Therapeutics, a clinical-stage biotechnology company, announced today that the U.S. Food...
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Zacks via Yahoo Finance· 4 days agoNomlabofusp has received Rare Pediatric Disease designation, Fast Track designation and Orphan Drug ...
Sobi North America Gets FDA Fast Track Designation for Rheumatic Disease Complication Treatment
Market Watch· 2 days agoThe Waltham, Mass.-based affiliate of Swedish Orphan Biovitrum said Friday that the U.S. Food and Drug Administration had granted the designation ...
Vedanta Biosciences doses first subject in Phase III C difficile prevention trial
Clinical Trials Arena via Yahoo Finance· 4 days agoIt consists of a specifically designed bacterial consortium and has been recognised by the US Food...
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
FOX 4 Kansas City· 6 days agoKS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo ...
Biogen is buying up an immune drug developer for $1.8 billion
Quartz· 4 days agoBiotechnology giant Biogen said on Wednesday that it is acquiring immune drug developer Human...